Propionic acidemia is an uncommon but important cause of metabolic cardiomyopathy because of an enzyme defect that impairs the metabolism of proteins and fats. Dietary nonadherence in patients with ...

About Propionic Acidemia Propionic acidemia is a rare, serious, inherited metabolic disorder with significant morbidity and mortality, affecting one in 100,000-150,000 individuals worldwide.

Recordati Rare Diseases: Carbaglu® (carglumic acid) tablets 200mg receives U.S. FDA approval for a new indication to treat acute hyperammonemia associated with propionic acidemia and ...

The Food and Drug Administration (FDA) has granted Fast Track designation to mRNA-3927 (Moderna), an investigational mRNA therapeutic for propionic acidemia (PA).

“Fast Track designation underscores the urgent need for a therapy that treats the underlying cause of propionic acidemia,” said Tal Zaks, M.D., Ph.D., chief medical officer at Moderna. “We ...

The propionic acidemia market size has grown steadily in recent years. It will grow from $2.00 billion in 2024 to $2.09 billion in 2025 at a compound annual growth rate CAGR of 4.8%.

CAMBRIDGE, MA / ACCESSWIRE / April 3, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that interim data for a first-in-human, phase 1/2, open-label, dose optimization study and extension study, ...

CAMBRIDGE, MA / ACCESSWIRE / April 3, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that interim data for a first-in-human, phase 1/2, open-label, dose optimization study and extension study ...